Friday, June 20, 2025
FDA Update: Larimar Breakthrough Friedreich's Ataxia Drug Faces Regulatory Milestone
Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotech company specializing in rare disease treatments, has scheduled a conference call and webcast for June 23, 2025, at 8:00 am EDT. The purpose of the call is to provide regulatory updates regarding their nomlabofusp clinical development program for Friedreich's Ataxia treatment. Participants can join via webcast or by dialing 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13754491. An archived version of the webcast will be available on Larimar's website after the live event.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.